William Johnson, DO

Medical Oncologist

Clinical Expertise

Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma; T Cell Lymphoma; Cutaneous T Cell lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma

Contact and Location

Speaks English

New York City

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

DO, The Philadelphia College of Osteopathic Medicine

Residencies

Internal Medicine - Lankenau Medical Center

Fellowships

Hematology and Medical Oncology - Thomas Jefferson University

Board Certifications

Internal medicine; Hematology; Medical Oncology

I am a board-certified medical oncologist trained in both hematology and medical oncology. My focus is on caring for people with lymphoma who are admitted to the hospital. I oversee the care of people who have recently received a lymphoma diagnosis, patients needing lymphoma therapy in the hospital setting, and those who have been admitted for any other reason associated with their lymphoma. I work closely with the entire team of lymphoma specialists, both within the Department of Medicine and across other departments. At MSK, we emphasize this team approach in order to provide the best care for our patients. My goal is to make your hospital stay as pleasant, seamless, and stress-free as possible.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Lymphoma Service doctors

Clinical Trials

Clinical Trials Co-Investigated by Dr. Johnson
A Phase II Study of AFM13 in People with T-Cell Lymphoma that Has Not Responded to Treatment

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Johnson WT, Bharel S, Klumpp T, et al. Impaired CD4+ T-Cell Recovery After Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. February 2020.

Johnson WT, Mishra A. The EZ-riding NK/T-cell Lymphoma. Blood commentary on “MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.” Blood, 2019;134(23):1999-2000. DOI: 10.1182/blood.2019003023.

Johnson WT, Kartan S, Nikbakht N, Porcu P. A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial. American Society of Hematology. December 2019.

Johnson WT, Mishra A, Binder A, Gru A, Porcu P. Mogamulizumab versus Investigator’s Choice in Relapsed/Refractory Adult T-Cell Leukemia/Lymphoma: All Four One or None for All? Editorial on “Mogamulizumab versus Investigator’s Choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.” Haematologica, 2019;104(5):864-67. DOI: 10.3324/haematol.2018.214536.

Johnson WT, Garfunkle D, Misung Y, et al. Outcomes of Methotrexate-associated T-cell and NK/T-cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-association and Response to MTX Withdrawal. Society of Hematologic Oncology. September 2019.

Johnson WT, Mukherji R, Kartan S, Nikbakht N, Porcu P, Alpdogan O. Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Concise Review. Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2018.10.03.

Alpdogan O, Kartan S, Johnson WT, Sokol K, Porcu P. Systemic Therapy for Cutaneous T-cell Lymphoma (CTCL). Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2019.01.02.

Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P. The Spectrum of CD30+ T-cell Lymphoproliferative Disorders in the Skin. Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2018.12.03.

Sokol K, Kartan S, Johnson WT, et al. Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). Front Oncol, 2019;9:509. DOI: 10.3389/fonc.2019.00509.

Johnson WT, Patel P, Hernandez A, et al. Langerhans Cell Histiocytosis and Erdheim-Chester Disease, both with Cutaneous Presentations, and Papillary Thyroid Carcinoma All Harboring the BRAFV600E Mutation. J Cutan Pathol, 2016;43(3): 270–75. DOI: 10.1111/cup.12636.

Johnson WT, Leeman-Neil R, Patel P. A Fatal Case of Primary Cutaneous Aggressive T-cell Lymphoma Switching from a CD4+ to a CD8+ Phenotype: Progressive Disease with Bexarotene and Romidepsin Treatment. Am J Dermatopath, 2016;38(11):832–37. DOI: 10.1097/DAD.0000000000000609.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

William Johnson discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures